Evidence map›Paper›PMID 35101098›Full record

Trial reportTrials2022

Paediatric Acute Respiratory Distress Syndrome Neuromuscular Blockade study (PAN-study): a phase IV randomised controlled trial of early neuromuscular blockade in moderate-to-severe paediatric acute respiratory distress syndrome.

Michelle W Rudolph, Sjoerdtje Slager, Johannes G M Burgerhof, Job B M van Woensel, Jan-Willem C Alffenaar, Roelie M Wösten-van Asperen, Matthijs de Hoog, Marloes M IJland, Martin C J Kneyber, SKIC research consortium

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02902055 (Life-threatening Acute Respiratory Failure in Children), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02902055 phase4terminatednot on this map

Life-threatening Acute Respiratory Failure in Children: to Breathe or Not to Breathe Spontaneously, That's the Question

TypeinterventionalSponsorUniversity Medical Center GroningenRan2019 to 2024Enrolled3ConditionsARDSArmsNeuromuscular Blocking Agents, Isotonic saline
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Michelle W RudolphDepartment of Paediatrics, Division of Paediatric Critical Care Medicine, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-1386-293X
Sjoerdtje SlagerDepartment of Paediatrics, Division of Paediatric Critical Care Medicine, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Johannes G M BurgerhofDepartment of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Job B M van WoenselDepartment of Paediatric Intensive Care, Emma Children's Hospital/Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Jan-Willem C AlffenaarDepartment of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Roelie M Wösten-van AsperenPaediatric Intensive Care Unit, Wilhelmina Children's Hospital/University Medical Centre Utrecht, Utrecht, The Netherlands.
Matthijs de HoogIntensive Care Unit, Departments of Paediatrics and Paediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Marloes M IJlandDepartment of Paediatric Intensive Care, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Martin C J KneyberDepartment of Paediatrics, Division of Paediatric Critical Care Medicine, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. m.c.j.kneyber@umcg.nl.
SKIC research consortium
University Medical Center Groningen · NLEmma Kinderziekenhuis · NLErasmus MC - Sophia Children’s Hospital · NLRadboud University Nijmegen · NLThe University of Sydney · AUWilhelmina Children's Hospital · NL

Funding

ZonMw 848041002
6 · The paper itself

Abstract

backgroundPaediatric acute respiratory distress syndrome (PARDS) is a manifestation of severe, life-threatening lung injury necessitating mechanical ventilation with mortality rates ranging up to 40-50%. Neuromuscular blockade agents (NMBAs) may be considered to prevent patient self-inflicted lung injury in PARDS patients, but two trials in adults with severe ARDS yielded conflicting results. To date, randomised controlled trials (RCT) examining the effectiveness and efficacy of NMBAs for PARDS are lacking. We hypothesise that using NMBAs for 48 h in paediatric patients younger than 5 years of age with early moderate-to-severe PARDS will lead to at least a 20% reduction in cumulative respiratory morbidity score 12 months after discharge from the paediatric intensive care unit (PICU).

methodsThis is a phase IV, multicentre, randomised, double-blind, placebo-controlled trial performed in level-3 PICUs in the Netherlands. Eligible for inclusion are children younger than 5 years of age requiring invasive mechanical ventilation with positive end-expiratory pressure (PEEP) ≥ 5 cm H

trial registrationClinicalTrials.gov NCT02902055 . Registered on September 15, 2016.

Indexed as

Neuromuscular BlockadeNeuromuscular Blocking AgentsRespiratory Distress SyndromeAdultChildHumansInfantIntensive Care Units, PediatricRespiration, ArtificialNeuromuscular Blocking AgentsAcute respiratory distress syndromeChildrenCritical illness polyneuropathy and myopathyMechanical ventilationNeuromuscular blockadeRespiratory morbidityRespiratory morbidity score

Identifiers

PMID35101098
PMCPMC8802263
OpenAlexW4210498670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.